New and emerging pharmacological treatment options for acromegaly

Expert Opin Pharmacother. 2021 Mar 30. doi: 10.1080/14656566.2021.1908998. Online ahead of print.ABSTRACTINTRODUCTION: Transsphenoidal surgery is the first-line treatment for acromegaly, but even in referral centers, approximately 50% of patients are not cured, and adjuvant pharmacological treatment is necessary. Widely used therapies encompass different drug classes, such as injectable somatostatin receptor ligands (SRLs), oral dopamine agonists and injectable growth hormone receptor antagonists, but approximately 40% of patients still have disease activity in real-life practice. Therefore, there is a need for new medical therapies to allow disease control in a larger proportion of patients, increase quality of life, reduce morbidity and mortality and improve treatment adherence in acromegaly.AREAS COVERED: In this review, the authors cover new and emerging drugs under development or drugs recently approved for the treatment of acromegaly.EXPERT OPINION: Disease control is essential to reduce morbidity and mortality in acromegaly but is still not achieved in a significant proportion of patients or takes a long time to be achieved with currently available options and treatment algorithms. Therefore, the development of new drugs as well as the establishment of biomarkers of disease control to allow precision medicine will improve treatment and outcomes in acromegaly.PMID:33783289 | DOI:10.1080/14656566.2021.1908998
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research